M&A

Investor opposition to Bristol-Myers’ $74B Celgene buyout grows as activist Starboard joins the rebellion

/>

by — on
Updated:

Bristol-Myers Squibb and Celgene have a big problem on their hands.

After the market closed Wednesday, Bristol-Myers’ largest investor, Wellington Management, moved to voice its opposition to the company's $74 billion mega-merger with Celgene. Some analysts — though not all — immediately flagged the move as a real threat to the deal, raising the risk that a major move like this could stir a widespread rebellion among shareholders.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription
GMP Biomanufacturing Operator
Aldevron Fargo, ND
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA
Visit Endpoints Careers ->